Upstream Bio (UPB) Depreciation & Amortization (CF) (2023 - 2026)
Upstream Bio (UPB) recorded quarterly Depreciation & Amortization (CF) of $49000.0 in Q1 2026, down 51.0% quarter-over-quarter from $100000.0 in Q4 2025, and up 13.95% on a YoY basis from $43000.0 in Q1 2025.
Upstream Bio (UPB) Depreciation & Amortization (CF) (2023 - 2026) Analysis & Trends
Upstream Bio's Depreciation & Amortization (CF) history runs 4 years deep, the most recent figure standing at $49000.0 for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) rose 13.95% year-over-year to $49000.0; the TTM figure through Mar 2026 stood at $349000.0 (up 19.52% YoY), while the FY2025 annual figure was $200000.0, up 124.72% from the prior year.
- Depreciation & Amortization (CF) was $49000.0 for Q1 2026 at Upstream Bio, down from $100000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $100000.0 in Q3 2023 to a low of $13000.0 in Q1 2024.
- Historically, Depreciation & Amortization (CF) has averaged $69818.2 across 4 years, with a median of $100000.0 in 2023.
- Biggest YoY gain for Depreciation & Amortization (CF) was 250.0% in 2024; the steepest drop was 0.0% in 2024.
- A 4-year view of Depreciation & Amortization (CF) shows it stood at $14000.0 in 2023, then surged by 250.0% to $49000.0 in 2024, then jumped by 104.08% to $100000.0 in 2025, then sank by 51.0% to $49000.0 in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $49000.0 (Q1 2026), $100000.0 (Q4 2025), and $100000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1,395.22 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 429,663.65 |
| 10 | Upstream Bio | 339.03 Mn | 339.03 Mn | -3.94 Mn | 49,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 49,000.00 |
| Mar 31, 2026 | 49,000.00 |
| Dec 31, 2025 | 100,000.00 |
| Dec 31, 2025 | 100,000.00 |
| Sep 30, 2025 | 100,000.00 |
| Sep 30, 2025 | 100,000.00 |
| Jun 30, 2025 | 100,000.00 |
| Jun 30, 2025 | 100,000.00 |
| Mar 31, 2025 | 43,000.00 |
| Mar 31, 2025 | 43,000.00 |
| Dec 31, 2024 | 49,000.00 |
| Dec 31, 2024 | 49,000.00 |
| Sep 30, 2024 | 100,000.00 |
| Sep 30, 2024 | 100,000.00 |
| Jun 30, 2024 | 100,000.00 |
| Jun 30, 2024 | 100,000.00 |
| Mar 31, 2024 | 13,000.00 |
| Mar 31, 2024 | 13,000.00 |
| Dec 31, 2023 | 14,000.00 |
| Dec 31, 2023 | 14,000.00 |